Jerusalem Pharmaceuticals Statistics

Total Valuation

Jerusalem Pharmaceuticals has a market cap or net worth of JOD 45.73 million. The enterprise value is 41.68 million.

Market Cap	45.73M
Enterprise Value	41.68M

Important Dates

The last earnings date was Thursday, October 31, 2024.

Earnings Date	Oct 31, 2024
Ex-Dividend Date	n/a

Share Statistics

Jerusalem Pharmaceuticals has 18.00 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	18.00M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.07%
Owned by Insiders (%)	42.26%
Owned by Institutions (%)	5.95%
Float	6.90M

Valuation Ratios

The trailing PE ratio is 12.37.

PE Ratio	12.37
Forward PE	n/a
PS Ratio	1.72
PB Ratio	1.00
P/TBV Ratio	n/a
P/FCF Ratio	14.14
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.88, with an EV/FCF ratio of 12.88.

EV / Earnings	11.29
EV / Sales	1.57
EV / EBITDA	6.88
EV / EBIT	8.37
EV / FCF	12.88

Financial Position

The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.03.

Current Ratio	3.57
Quick Ratio	2.51
Debt / Equity	0.03
Debt / EBITDA	0.24
Debt / FCF	0.44
Interest Coverage	77.17

Financial Efficiency

Return on equity (ROE) is 8.10% and return on invested capital (ROIC) is 6.47%.

Return on Equity (ROE)	8.10%
Return on Assets (ROA)	5.20%
Return on Capital (ROIC)	6.47%
Revenue Per Employee	50,806
Profits Per Employee	7,058
Employee Count	523
Asset Turnover	0.44
Inventory Turnover	1.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.85% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+0.85%
50-Day Moving Average	3.73
200-Day Moving Average	3.59
Relative Strength Index (RSI)	36.01
Average Volume (20 Days)	2,941

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Jerusalem Pharmaceuticals had revenue of JOD 26.57 million and earned 3.69 million in profits. Earnings per share was 0.21.

Revenue	26.57M
Gross Profit	14.20M
Operating Income	4.97M
Pretax Income	4.82M
Net Income	3.69M
EBITDA	5.77M
EBIT	4.97M
Earnings Per Share (EPS)	0.21

Full Income Statement

Balance Sheet

The company has 6.15 million in cash and 1.42 million in debt, giving a net cash position of 4.73 million or 0.26 per share.

Cash & Cash Equivalents	6.15M
Total Debt	1.42M
Net Cash	4.73M
Net Cash Per Share	0.26
Equity (Book Value)	46.22M
Book Value Per Share	2.53
Working Capital	25.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.78 million and capital expenditures -1.55 million, giving a free cash flow of 3.24 million.

Operating Cash Flow	4.78M
Capital Expenditures	-1.55M
Free Cash Flow	3.24M
FCF Per Share	0.18

Full Cash Flow Statement

Margins

Gross margin is 53.44%, with operating and profit margins of 18.72% and 13.89%.

Gross Margin	53.44%
Operating Margin	18.72%
Pretax Margin	18.15%
Profit Margin	13.89%
EBITDA Margin	21.70%
EBIT Margin	18.72%
FCF Margin	12.17%

Dividends & Yields

This stock pays an annual dividend of 0.07, which amounts to a dividend yield of 2.79%.

Dividend Per Share	0.07
Dividend Yield	2.79%
Dividend Growth (YoY)	-33.42%
Years of Dividend Growth	2
Payout Ratio	29.86%
Buyback Yield	n/a
Shareholder Yield	2.79%
Earnings Yield	8.07%
FCF Yield	7.07%

Dividend Details

Stock Splits

The last stock split was on August 1, 2013. It was a forward split with a ratio of 1.4216864044.

Last Split Date	Aug 1, 2013
Split Type	Forward
Split Ratio	1.4216864044

Scores

Jerusalem Pharmaceuticals has an Altman Z-Score of 4.05.

Altman Z-Score	4.05
Piotroski F-Score	n/a